Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.

Progress and challenges in anti-obesity pharmacotherapy

Bessesen, Daniel H, Van Gaal, Luc F · 2018 · The Lancet Diabetes & Endocrinology

Abstract

Obesity is a serious and growing worldwide health challenge. Healthy lifestyle choices are the foundation of obesity treatment. However, weight loss can lead to physiological adaptations that promote weight regain. As a result, lifestyle treatment alone typically produces only modest weight loss that is difficult to sustain. In other metabolic diseases, pharmacotherapy is an accepted adjunct to lifestyle. Several anti-obesity drugs have been approved in the USA, European Union, Australia, and Japan including sympathomimetics, pancreatic lipase inhibitors, GABA A receptor activators, a serotonin 2C receptor agonist, opioid antagonist, dopamine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs vary in their efficacy and side-effect profiles but all provide greater weight loss than do lifestyle changes alone. Even though obesity is widespread and associated with adverse health consequences, and anti-obesity drugs can help people to lose weight, very few patients use these drugs partly because of concerns about safety and efficacy, but also because of inadequate health insurance coverage. Despite great advances in our understanding of the biology of weight regulation, many clinicians still believe that patients with obesity should have the willpower to eat less. The tendency to hold the patient with obesity responsible for their condition can be a barrier to greater acceptance of anti-obesity drugs as appropriate options for tre…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30236-x

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 115 references

Cited by

See all 348

Metadata

Authors
Bessesen, D. H., & Van Gaal, L. F.
Affiliations
Denver Health Medical Center (US)
Corresponding author
Bessesen, Daniel H
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-03
Volume
6
Issue
3
Pages
237-248
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2754824139
Cited by
347
References
115
Citations by year
2026: 19 · 2025: 40 · 2024: 65 · 2023: 55 · 2022: 49 · 2021: 47 · 2020: 30 · 2019: 23 · 2018: 17
FWCI
2.43
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity, anti-obesity drugs, pharmacotherapy, weight loss, weight regain, lifestyle intervention, GLP-1 receptor agonists, sympathomimetic drugs, pancreatic lipase inhibitors, GABA-A receptor agonists, opioid antagonists, health insurance coverage, body weight regulation, glucose-dependent insulinotropic polypeptide, glucagon, drug development pipeline
MeSH terms
Humans, Obesity, Prognosis, Weight Loss, Anti-Obesity Agents, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progress and challenges in anti-obesity pharmacotherapy. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30236-x
The paper
Bessesen, D. H., & Van Gaal, L. F. (2018). Progress and challenges in anti-obesity pharmacotherapy. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30236-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.